<DOC>
	<DOC>NCT02926586</DOC>
	<brief_summary>The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with core-binding factor acute myeloid leukemia</brief_summary>
	<brief_title>Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Clinical and laboratory diagnosis of CBFAML,including RUNX1RUNX1T1 and CBFMYH11 fusion gene rearrangement by PCR/FISH In status of complete remission after one to two courses of induction therapy Total bilirubinic acid ≤ 35μmol/L, AST/ALT&lt;2 times abnormal level, serum creatinine &lt; 1.5mg/ml Cardiac function: EF ≥ 50% Hydroxyurea can be used for patient with white blood cell count ≥ 50*109/L ECOG (Eastern Cooperative Oncology Group) score: ≤ 2 Relapsed/refractory AML Serious liver/ kidney dysfunction Cardiac function level: 2 above Female in pregnancy or lactation With serious infection diseases or other diseases Not obey the principle of clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RUNX1-RUNX1T1</keyword>
	<keyword>CBFβ-MYH11</keyword>
	<keyword>fludarabine</keyword>
	<keyword>cytarabine</keyword>
</DOC>